Ms. Wright-Mitchell serves as fractional legal advisor and compliance advisor.
Jane Wright Mitchell, Pharm.D., J.D.
CUMBERLAND, Md., April 25, 2024 (Globe Newswire) — RS BioTherapeutics is on a mission to develop life-changing medicines for millions of people suffering from diseases characterized by lung inflammation. , we are pleased to announce the addition of Jane Wright. Mitchell, PharmD, JD, member of the RS BioTherapeutics Business Advisory Board. As a member of the Business Advisory Board, Ms. Wright-Mitchell also serves as Fractional General Counsel and Compliance Advisor to RS BioTherapeutics.
Commenting on the addition of Mr. Wright-Mitchell to the Business Advisory Board, Dean Hart, Chief Executive Officer of RS BioTherapeutics, said: Advisory body. Jane is a great fit for our goal of adding business advisors who go beyond their core areas of expertise to make our organization better. ”
Ms. Wright-Mitchell is a healthcare and life sciences attorney with over 20 years of experience working with pharmaceutical and medical device companies. She currently serves as President and General Counsel of Lecar Life Sciences, Inc., her consulting company. In this role, she serves as general counsel for several companies in the pharmaceutical, medical device, medical technology, and cannabis industries. Previously, she served as General Counsel, Chief Compliance Counsel, and Corporate Secretary for Vaxcyte, Inc., a vaccine development company. Prior to joining Vaxcyte, she served as Chief Legal Officer of Steep Hill, Inc., a California licensed cannabis testing laboratory. She currently owns New Frontier Data, a data, analytics and technology company focused on the global cannabis industry, and Canbud Distribution Corp., a publicly traded Canadian company with a fully integrated and licensed hemp business. Serving as a director.
Commenting on her appointment to RS Biotherapeutics' Business Advisory Board, Ms. Wright-Mitchell said: People suffering from diseases characterized by inflammation of the lungs. ”
Ms. Wright-Mitchell earned a Bachelor of Science in Biological Sciences from Clemson University, a Pharm.D. from the University of Illinois at Chicago, and a Juris Doctorate from Chicago-Kent College of Law. She is registered to practice with the U.S. Patent and Trademark Office and is also registered as a Certified Pharmacist (Illinois).
About RS Biotherapeutics
RS BioTherapeutics' mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by lung inflammation. RS BioTherapeutics is launching a first-in-class steroid-free multitargeted immunomodulator (RSBT) for the treatment of respiratory diseases characterized by pulmonary inflammation associated with idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). -001) is being developed. ) as the initial indication. RS BioTherapeutics owns the exclusive worldwide license for his RSBT-001, and in 2026 he plans to submit an investigational new drug application for RSBT-001 and begin human trials. For more information about RS BioTherapeutics, please visit www.rsbiotherapeutics.com.
Media contact:
David Gutierrez, Dresner Corporate Services at RS BioTherapeutics, (312) 780-7204, dgutierrez@dresnerco.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1392699b-89b6-4eb9-af9b-058f53c10999.
